Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907329 | 0.81 | KDM4E (0.62) | PARP1PIM1KDM4EKMT2A | |
| SCHEMBL9907986 | 0.78 | HTR5A (0.47) | SLC9A1PIM1HTR2BHTR7 | |
| SCHEMBL9907327 | 0.74 | PDCD1 (0.45) | KDM4EKMT2A | |
| SCHEMBL5425136 | 0.74 | MGAM (0.58) | SLC9A1KDM4EKMT2A | |
| SCHEMBL7923246 | 0.72 | SLC9A1 (0.55) | SLC9A1HTR2BHTR7 | |
| SCHEMBL16502777 | 0.70 | HTR2B (0.53) | SLC9A1HTR2BHTR7 | |
| SCHEMBL27416309 | 0.70 | PARP1 (0.61) | PARP1BCAT2KDM4E | |
| SCHEMBL15603374 | 0.69 | SLC9A1 (0.64) | SLC9A1HTR2BHTR7 | |
| SCHEMBL12858178 | 0.69 | P2RX7 (0.54) | SLC9A1PARP1PLAU | |
| SCHEMBL28724659 | 0.69 | ALDH1A1 (0.43) | PARP1PLAUKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SLC9A1 1181/4885PARP1 1373/4885PLAU 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.